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Abstract
Background—Disruptions in perception and cognition are characteristic of psychiatric conditions
such as schizophrenia. Studies of pharmacological agents that alter perception and cognition in
humans might provide a better understanding of the brain substrates of these complex processes. One
way to study these states in rodents is with tests that require attention and visual perception for correct
performance.
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Methods—We examined the effects of two drugs that cause disruptions in perception and cognition
in humans—the kappa-opioid receptor (KOR) agonist salvinorin A (salvA; 0.125–4.0 mg/kg) and
the non-competitive NMDA receptor antagonist ketamine (0.63–20 mg/kg)—on behavior in rats
using the 5-choice serial reaction time task (5CSRTT), a food-motivated test that quantifies attention.
We also compared the binding profiles of salvA and ketamine at KORs and NMDA receptors.
Results—SalvA and ketamine produced the same pattern of disruptive effects in the 5CSRTT,
characterized by increases in signs often associated with reduced motivation (omission errors) and
deficits in processing (elevated latencies to respond correctly). Sessions in which rats were fed before
testing suggest that reduced motivation produces a subtly different pattern of behavior. Pretreatment
with the KOR antagonist JDTic (10 mg/kg) blocked all salvA effects and some ketamine effects.
Binding and function studies revealed that ketamine is a full agonist at KORs, although not as potent
or selective as salvA.
Conclusions—SalvA and ketamine have previously underappreciated similarities in their
behavioral effects and pharmacological profiles. By implication, KORs might be involved in some
of the cognitive abnormalities observed in psychiatric disorders such as schizophrenia.
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Introduction
Disruptions in perception and cognition are characteristic of psychiatric conditions such as
schizophrenia and bipolar disorder (Chen and Faraone 2000; Cornblatt and Malhotra 2001;
Clark et al. 2002). Pharmacological agents that alter perception and cognition in humans are
often used to study the brain substrates of these complex processes. For example, it is often
reported that intoxication with the non-competitive NMDA receptor antagonist phencyclidine
(PCP) in humans produces virtually all of the symptoms of schizophrenia (Javitt and Zukin
1991; Jentsch and Roth 1999; Morris et al. 2005). Similarly, the non-competitive NMDA
receptor antagonist ketamine has been used in humans to study dissociative states and
schizophrenia (Lahti et al. 2001; Krystal et al. 2003, 2005). Ketamine also disrupts attention
and working memory in humans (Parwani et al. 2005), and related NMDA receptor antagonists
(i.e., PCP, MK-801) impair attention and impulse control in rodents (Amitai et al. 2007; Paine
et al. 2007). Together these studies suggest that blockade of NMDA receptors is sufficient to
produce hallmark signs of schizophrenia. However, recent work suggests that other
mechanisms are also sufficient to produce some of these signs, including selective stimulation
of kappa-opioid receptors (KORs). Salvinorin A (salvA), the active component of the plant
Salvia divinorum, is becoming increasingly recognized for its psychotropic effects in humans
(Vortherms and Roth 2006). This drug can induce various symptoms of psychiatric disorders,
including dissociation, perceptual distortions, depersonalization, feelings of spatiotemporal
dislocation, and anxiety (Valdes 1994; Siebert 1994; González et al. 2006). Considering that
receptor screening assays indicate that salvA binds almost exclusively to KORs (Roth et al.
2002; Chavkin et al. 2004), studies of this substance have the potential to provide new insights
on the neurobiology of perception and the mechanisms of psychiatric disorders.
Recent developments have piqued interest in ketamine and salvA. Ketamine produces rapid
and long-lasting antidepressant effects in humans with treatment-resistant depression (Zarate
et al. 2006), raising the possibility that NMDA antagonists might have utility in the treatment
of mood disorders. SalvA has become a popular recreational drug that is marketed primarily
to adolescents and young adults as a safe and legal hallucinogen (González et al. 2006).
Interestingly, there are anecdotal reports that salvA can occasionally produce antidepressant
effects in humans (Hanes 2001), although most studies in humans and laboratory animals
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suggest that salvA and other KOR agonists produce acute states of aversion, dysphoria, and
anxiety (Pfeiffer et al. 1986; Wadenberg 2003; Zhang et al. 2005; Carlezon et al. 2006;
González et al. 2006). The fact that both ketamine and salvA appear to cause disruptions in
perception and cognition provides a rationale for studies in which their effects are directly
compared, particularly since it seems conceivable that these effects are somehow related to
subsequent effects on mood.
The present studies were designed to compare the effects of salvA and ketamine in the 5-choice
serial reaction time task (5CSRTT) in rats. The 5CSRTT is a food-motivated attention test that
is analogous to the continuous performance task used to study attention in humans (Rosvold
et al. 1956; Robbins 2002). It is well-suited to characterize the effects of psychotropic drugs
because it yields metrics that quantify attention, reaction time, motivation, and impulsivity
(Robbins 2002; Paine et al. 2007, 2009). We used the KOR antagonist JDTic to evaluate the
role of KORs in the effects of salvA and ketamine and, for comparison, we examined the effects
of a non-pharmacological manipulation (pre-feeding immediately before testing) designed
specifically to affect the food-motivated elements of the task. When we discovered that salvA
and ketamine produced many similar effects on behavior in the 5CSRTT, we performed
receptor-binding studies (Jensen and Roth 2008) to determine if there are any similarities in
their pharmacologic and functional profiles.
Methods
Drugs
Dried S. divinorum leaves were purchased from Salvia Space (Lawrence, KS). SalvA was
extracted, isolated, and purified as described previously (Carlezon et al. 2006). Spectroscopic
analyses confirmed that the salvA obtained with these methods is chemically identical to that
described in other reports (Roth et al. 2002). The samples used for testing were determined by
high-pressure liquid chromatography (HPLC) to be >99% pure, and were dissolved in a vehicle
of 75% dimethyl sulfoxide (DMSO)–25% distilled water. Ketamine (Sigma, St. Louis MO)
was dissolved in physiological saline. JDTic (Research Triangle Park, NC; see Beardsley et
al. 2005; Knoll et al. 2007) was dissolved in distilled water. Drugs were administered via
intraperitoneal (IP) injection in a volume of 1 ml/kg at doses with behavioral effects in other
tests (see below).
Animals
Nineteen male Sprague–Dawley rats (Charles River; 250–300 g at the start of the experiment)
were housed in pairs in clear Plexiglas cages on a 12-h/12-h light–dark cycle (lights on at 0700
h). Rats were given 1 week to acclimate to the housing conditions; during this period, food
(Purina Rat Chow) and water were freely available. Beginning 24 h prior to training and through
the duration of the experiments, rats were food restricted such that they maintained 85% of
their free-feeding weight. With the exception of Experiment 3 (below), rats were given a daily
ration of chow (~17 g) immediately after training or testing sessions. Experiments were
conducted in accordance with the Guide for the Care and Use of Laboratory Animals (National
Academy Press, 1996) and McLean Hospital policies.
Behavioral training
Testing was conducted in six 5CSRTT operant conditioning chambers housed in sound-
attenuating ventilated cubicles (Med-Associates, St. Albans VT). Five equally spaced
2.5×2.5×2.2-cm apertures were set into a curved aluminum front wall; each aperture was fitted
with a yellow LED stimulus light (6.4 mm in diameter) and an infrared detector (1.0 cm from
the front of the aperture). The opposite wall was fitted with a food magazine connected to a
45-mg pellet dispenser; an infrared detector located horizontally across the magazine allowed
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for the detection of nosepokes into the magazine. The top of the magazine was fitted with a
light (1.0 cm in diameter). The house light was located on the ceiling directly above the
magazine. The sidewalls and ceiling were made of clear polycarbonate, and the floor was a
stainless steel grid.
As described previously (Paine et al. 2007), rats were first trained to retrieve food pellets (45
mg, Bio-Serv #F0021, Frenchtown NJ) from the food magazine. Rats were then trained to
detect the presentation of a brief stimulus light at one of five spatial locations. Initially, the
duration of the stimulus light (discriminative stimulus; DS) was 30 s, the inter-trial interval
(ITI) was 2 s, the limited hold (duration from the onset of stimulus light in which the rat was
able to respond) was 30 s and the time-out was 2 s; these were gradually adjusted across training
sessions to the final durations described below. Sessions started with the delivery of one food
pellet; the first trial commenced when the rat retrieved the food pellet. Nosepoking in the
magazine initiated a 5-s ITI during which the house light was turned on. At the end of the ITI,
a 1.0-s light stimulus was presented at the rear of one of the five stimulus locations (apertures).
Rats had up to 5 s (limited hold) to make a response. A response in this aperture was termed a
correct response and resulted in the delivery of one food pellet and illumination of the magazine
light; the magazine light remained illuminated for 5 s following food pellet delivery. Nosepokes
in the remaining apertures during the limited hold were considered incorrect responses and
resulted in a 5-s time-out during which the house light was extinguished. Similarly, failing to
respond during the limited hold (i.e., an omission) resulted in a 5-s time-out. Responses
occurring prior to stimulus presentation (i.e., during the ITI) were termed premature responses
and resulted in a 5-s time-out. Responses occurring during the time-out period had no
programmed consequences. Each session consisted of 90 trials or terminated after 30 min,
whichever came first. Performance measures of primary interest were: % correct ((correct
responses / [correct + incorrect + omitted responses]) × 100), accuracy ((correct responses /
[correct + incorrect responses]) × 100), % omissions ([total omissions / number of trials] ×
100), premature responses (responses during the ITI), correct response latency (the time from
the stimulus onset to a correct response), and reward latency (the time from a correct response
to the collection of the food pellet). Subjects were considered to have acquired the task when
their behavior stabilized, as reflected by greater than 60% accuracy and fewer than 20%
omissions for three consecutive days.
Behavioral testing
A total of four separate experiments were conducted. Experiments 1–3 involved all rats,
whereas Experiment 4 involved only a subset from each treatment condition. Those rats not
used in Experiment 4 were used in pilot studies not described here.
Experiment 1—Rats received either salvA (n=10) or ketamine (n=9) 10 min prior to testing.
Drug doses (salvA, 0.125–4.0 mg/kg; ketamine, 0.625–20.0 mg/kg) were administered in an
ascending order, and vehicle was administered last. Drug sessions were separated by at least
three drug-free test sessions. Doses of salvA were based on Carlezon et al. (2006) and doses
of ketamine were based on Imre et al. (2006).
Experiment 2—After at least three drug-free test sessions, the effects of salvA and ketamine
on two variants of the standard 5CSRTT were assessed. Rats received the same drug as in
Experiment 1. First, the rats were tested in a version of the 5CSRTT that requires increased
attention, where the DS (stimulus light) was shortened from 1.0 to 0.5 s (Short DS). At least
3 days later, rats were tested in a version of the 5CSRTT that requires increased impulse control,
where the ITI was increased from 5 to 9 s (Long ITI). Since our working hypothesis was that
these versions of the task would be more difficult, we used doses of the drugs that were below
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those with detectable effects in the standard version of the 5CSRTT: rats were tested once with
salvA (1.0 mg/kg) or ketamine (5.0 mg/kg), and once with their respective vehicles.
Experiment 3—After at least seven drug-free test days, we performed a brief environmental
manipulation to determine if pre-feeding the rats—presumably reducing motivation for the
Bio-Serv pellets used to reward correct performance in the 5CSRTT—would mimic any of the
effects of salvA or ketamine. Rats were given their entire daily ration of chow (17 g) 30 min
prior to testing in the standard version of the 5CSRTT, as in Experiment 1.
Experiment 4—In a subset of rats (n=8), the ability of a KOR antagonist to block the
behavioral effects of salvA and ketamine was assessed. To confirm our initial findings
(Experiment 1), rats were first re-tested with salvA (2.0 mg/kg, IP) and ketamine (20 mg/kg,
IP) in two test sessions separated by at least 3 days. The order of salvA and ketamine
administration was counterbalanced across rats. All rats were then administered JDTic (10 mg/
kg, IP), a selective KOR antagonist known to have a slow onset (>24 h) and long duration (>3
weeks) of action (see Knoll and Carlezon 2010). This dose of JDTic has anxiolytic effects, but
does not affect locomotor activity in open field tests (Knoll et al. 2007). At 24 and 96 h after
JDTic, rats received salvA (2.0 mg/kg, IP) or ketamine (20 mg/kg, IP); the order of drug
administration was counterbalanced across rats. The effects of JDTic alone were evaluated in
a test conducted 72 h after administration.
Statistical analyses
Since a within-subjects design was used and each rat received multiple treatments, data were
analyzed using one-way (Treatment) analyses of variance (ANOVAs) with repeated measures
(Experiments 1 and 4) or t tests for correlated samples (Experiments 2 and 3). Significant effects
in the ANOVAs were further analyzed using post hoc Fisher’s protected t tests.
In vitro binding studies
Radioligand-binding assays at human-cloned KOR and rat brain σ and NMDA receptors were
performed by using the resources of the National Institute of Mental Health Psychoactive Drug
Screening Program (NIMH-PDSP). Specifically, KOR radioligand-binding assays were
performed using cloned human KOR (hKOR) and [3H] bremazocine as the radioligand. The
binding affinities for the σ receptor were determined using rat whole brain homogenates with
a protocol adapted from Kovács and Larson (1998) and [3H] pentazocine as the radioligand.
Finally, the affinities of the test compounds for the NMDA receptors were obtained using rat
whole brain homogenates and [3H] MK-801 as the radioligand. Detailed on-line protocols are
available for all assays at the NIMH-PDSP website
(http://pdsp.med.unc.edu/UNC-CH%20Protocol%20Book.pdf). Initial screening assays were
performed in quadruplicate using a 10-µM test compound, and the percent inhibition of specific
binding was determined. Where 10 µM of the test compound inhibited >50% of specific
binding, Ki determinations were performed by using six concentrations of unlabeled ligand
spanning a 10,000-fold dose range. Ki values were calculated by using GRAPHPAD PRISM
and represent the mean ± SEM of quadruplicate determinations. The potencies and efficacies
of salvA and ketamine on hKOR were determined by their abilities to regulate [35S] GTPγS
binding to membranes of CHO-hKOR cells as previously detailed (Yan et al. 2009).
Results
Behavioral testing
Experiment 1—SalvA affected correct responding (F[6,54]=6.99, P<0.01) (Fig. 1a): post
hoc analyses revealed that the drug reduced the percentage of correct responses at 2.0 mg/kg
(P<0.01) and at 4.0 mg/kg (P<0.01). This effect was not associated with changes in accuracy
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at any of the doses tested (F[6,54] = 1.22, not significant [n.s.]) (Fig. 1b). Rather, it was
associated with effects on omissions (F[6,54]=8.08, P<0.01) (Fig. 1c): salvA produced
significant increases in the percentage of trials during which the rats failed to respond at doses
of 2.0 mg/kg (P<0.01) and4.0 mg/kg (P<0.01). SalvA also affected correct response latency
(F[6,54]=4.48, P<0.01) (Fig. 1d): the drug increased latencies to respond correctly at 2.0 mg/
kg (P<0.01) and 4.0 mg/kg (P<0.01). SalvA had no effects on premature responding (F[6,54]
=0.83, n.s.; not shown) or the latency to retrieve the reward (F[6,54] = 1.90, n.s.; not shown).
Ketamine produced a similar profile. The drug affected correct responding (F[6,48]=2.43,
P<0.05) (Fig. 2a), reducing the percentage of correct responses at 20 mg/kg (P<0.01).
Ketamine did not affect accuracy at any of the doses tested (F[6,48]=0.81, n.s.) (Fig. 2b), but
it affected omissions (F[6,48]=3.20, P<0.01) (Fig. 2c), producing significant increases in the
percentage of trials during which the rats failed to respond at 20 mg/kg (P<0.01). It also affected
correct response latency (F[6,48]=2.47, P<0.05) (Fig. 2d), increasing latencies to respond
correctly at 20 mg/kg (P<0.05), with a trend at 10 mg/kg (P<0.10). Ketamine had no effects
on premature responding (F[6,48] = 0.80, n.s.; not shown) or the latency to retrieve the reward
(F[6,48]=0.41, n.s.; not shown).
Experiment 2—Neither of the manipulations intended to make the 5CSRTT more
challenging made performance deficits emerge after treatment with sub-effective doses of the
drugs. Administration of salvA (1.0 mg/kg) or ketamine (5.0 mg/kg) did not degrade
performance in the short DS (Table 1; all Ps>0.10) or long ITI (Table 2; all Ps>0.10) versions
of the task. There was a small but statistically significant effect of ketamine on latency to collect
the reward in the short DS task (P<0.05) that is consistent with improved performance on this
measure.
Experiment 3—Providing the rats with their normal daily ration of food 30 min before testing
produced some of the same effects as active doses of salvA and ketamine in the standard
(Experiment 1) version of the 5CSRTT. When compared to baseline (mean performance over
the preceding 3 days of testing without any treatments), pre-feeding reduced the percentage of
correct responding (t[18] =2.15, P<0.05) (Fig. 3a). As was the case with the drugs, pre-feeding
had no effect on accuracy (t[18]=0.62, n.s) (Fig. 3b), but it increased omissions (t[18]=2.97,
P<0.01) (Fig. 3c) and latencies to respond correctly (t[18]=4.11, P<0.01) (Fig. 3d). Unlike the
drugs, it also reduced premature responding (t[18]=3.21, P<0.01) (Fig. 3e) and increased
latencies to collect the food reward (t[18]=7.24, P<0.01) (Fig. 3f).
Experiment 4—Pretreatment with the selective KOR antagonist JDTic (10 mg/kg, IP, >24
h before testing) blocked all of the effects of salvA (2.0 mg/kg). It blocked the effect on correct
responding (F[3,21] = 14.9, P<0.01) (Fig. 4a): the percentage of correct responses was reduced
only in the salvA alone group (P<0.01). Similarly, it blocked effects on omissions (F[3,21] =
14.5, P<0.01) (Fig. 4b), with percent omissions elevated only in the salvA alone group
(P<0.01), and on latencies to respond correctly (F[3,21]=5.25, P<0.01) (Fig. 4c), with latencies
elevated only in the salvA alone group (P<0.01). JDTic alone did not affect any performance
measure, nor were there any interactions between JDTic and salvA on any other measures,
including accuracy, premature responding, latencies to collect the food reward, or head entries
(not shown).
Pretreatment with JDTic also blocked some effects of ketamine (20 mg/kg). It blocked the
effect on correct responding (F[3,21]=7.82, P<0.01) (Fig. 5a): the percentage of correct
responses was reduced only in the ketamine alone group (P<0.01). Similarly, it blocked effects
on omissions (F[3,21]=8.33, P<0.01) (Fig.5b): omissions were elevated only in the ketamine
alone group (P<0.01). However, JDTic did not block the effects of ketamine on latencies to
respond correctly (F[3,21]=8.46, P<0.01) (Fig. 5c): there were equivalent increases in latencies
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to respond correctly after ketamine in both the absence (P<0.01) and presence of JDTic
(P<0.01). Interestingly, there was evidence of synergistic effects between ketamine and JDTic,
as reflected by the emergence of behavioral patterns not caused by either drug alone. An effect
on premature responding emerged (F[3,21]=5.38, P<0.01) (Fig. 6a): treatment with ketamine
in the presence of JDTic caused a significant increase in premature responding (P<0.01). An
effect on the number of head entries into the food magazine—a measure not affected by any
drug treatment—also emerged (F[3,21]=4.63, P<0.05) (Fig. 6b): treatment with ketamine in
the presence of JDTic caused a significant increase in head entries (P<0.05). There were no
interactions between JDTic and ketamine on accuracy or latencies to collect the food reward.
In vitro binding studies
SalvA bound with high affinity to KORs and potently stimulated [35S] GTPγS, while having
negligible affinity for σ-opioid and NMDA receptors (Table 3). These findings confirm
previous reports describing the potency and selectivity of salvA (Roth et al. 2002;Chavkin et
al. 2004). Unexpectedly, ketamine also bound to KORs, though with a substantially lower
affinity and potency than at σ-opioid and NMDA receptors. Both salvA and ketamine displayed
full agonism at KORs, and the effects of each were completely blocked by 10 nM JDTic (Fig.
7).
Discussion
SalvA and ketamine produced similar effects in the 5CSRTT. Both drugs disrupted
performance, as reflected by decreases in the percentage of correct responses. Neither drug
affected accuracy, which provides a measure of how the rats perform on trials in which they
make a response. Rather, both drugs increased the percentage of trials in which the rats failed
to respond (omission errors). This pattern indicates that the decreases in correct responding
were caused by “omission errors” (failure to make a response) rather than “commission
errors” (responding at an incorrect aperture). Increases in omission errors were accompanied
by increases in the latency to make a correct response, an effect that might reflect reduced
speed of processing or decision-making (Robbins 2002; Paine et al. 2007). Neither drug
affected premature responding or the latency to collect the food reward following correct
responses, suggesting the absence of non-specific rate-reducing effects. The pattern of
behaviors emerged at a similar rate: the lowest doses of salvA and ketamine that reduced correct
responding produced increases in omissions and latencies to make a correct response without
significantly affecting the other metrics. Previous work (Paine et al. 2007) demonstrates that
the metrics used in this study can vary independently. For example, the NMDA antagonist
MK-801 decreases correct responding by increasing omissions. However, it also reduces
accuracy and increases premature responding at the same (or even lower) doses, perhaps
reflecting the non-specific stimulant effects of the drug. The tricyclic antidepressant
desipramine increases omissions and latencies to respond correctly, but it also reduces
premature responding and increases latencies to collect the food reward at the same doses,
perhaps reflecting non-specific rate-reducing effects of the drug. Of the psychotropic drugs we
have tested in the 5CSRTT, only one drug produces an identical pattern of effects as seen here
with salvA and ketamine: the selective KOR agonist U69,593, which shares discriminative
stimulus properties with salvA (Willmore-Fordham et al. 2007; Baker et al. 2009). Considering
the anecdotal similarities between some of the effects of salvA and ketamine in humans (Lahti
et al. 2001; Krystal et al. 2003; González et al. 2006), our data raise the possibility that the
specific pattern of behaviors seen in the present study—disrupted attentional performance
characterized by intact accuracy but increased omissions and decreased processing speed—is
a unique behavioral signature of drugs with dissociative effects.
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We previously reported that U69,593 disrupts performance in the 5CSRTT (Paine et al.
2007). We speculated that this effect might be related to a reduced motivation for the 45-mg
food pellets that reward correct performance in the 5CSRTT. Indeed, KOR agonists decrease
the rewarding effects of lateral hypothalamic brain stimulation (Todtenkopf et al. 2004),
cocaine (Crawford et al. 1995; Shippenberg et al. 1996; Tomasiewicz et al. 2008), and sexual
behavior (Leyton and Stewart 1992). We hypothesized that one way to reduce motivation for
the food reward without using a drug treatment would be to pre-feed the rats. In Experiment
3, we provided the rats with their daily ration of food (~17 g) 30 min before testing. Rats
maintained at 85% body weight typically eat this amount of food within 5 min. This
manipulation produced some of the same effects as salvA and ketamine: it increased omissions
and latencies to respond correctly without affecting accuracy. However, pre-feeding also
reduced premature responses and increased latency to collect the reward, which were not
affected by salvA or ketamine. This pattern of results suggests that the effects of salvA and
ketamine can be distinguished from pure reductions in motivation. Our data cannot rule out
the possibility that progressively higher doses of salvA and ketamine would eventually cause
similar effects on premature responses and latencies to collect the reward. It is important to
note that the rate of omissions was three to fourfold greater after treatment with active doses
of salvA and ketamine than after pre-feeding (compare Fig. 3c with Figs. 4b and 5b). This
suggests that the doses of salvA and ketamine were adequate to cause reductions in premature
responding and increases in latencies to collect the reward if these outcomes were inextricably
linked to increases in omissions.
The KOR selective antagonist JDTic (10 mg/kg) was administered once, 48 h before testing,
because this drug is known to have a slow onset (>24 h) and long duration (>3 weeks) of action
(Thomas et al. 2003; Knoll et al. 2007; Knoll and Carlezon 2010). We have shown previously
that this dose has anxiolytic effects in the elevated plus maze, but no effect on locomotor activity
in an open field (Knoll et al. 2007). Pretreatment with JDTic blocked all of the effects of salvA
in the 5CSRTT: it prevented the reductions in correct responding and the increases in omissions
and latencies to make a correct response. These data suggest that the ability of salvA to cause
these effects is entirely dependent on actions at KORs. Surprisingly, JDTic also blocked some
effects of ketamine: it prevented reductions in correct responding and increases in omission
errors, although it failed to affect latencies to make a correct response. One explanation for
this effect is that a subset of salvA and ketamine effects (reductions in correct responding and
increased omissions) is due to stimulation of KORs. Another possibility is that salvA and
ketamine cause similar effects through distinct mechanisms, and that JDTic blocks salvA
effects directly, but ketamine effects indirectly. In support of this possibility, JDTic and
ketamine had synergistic effects on some measures, making behaviors emerge that were not
seen with either drug alone. In the presence of JDTic, ketamine increased premature responding
and head entries into the food magazine, a measure not affected in our studies by any other
drug treatment. Common effects on brain dopamine (DA) may contribute to this effect: as one
example, extracellular concentrations of DA in the nucleus accumbens (NAc) are increased by
both NMDA antagonists (Imperato et al. 1990; Zhang et al. 1992) and KOR antagonists
(Maisonneuve et al. 1994). DA agonists can increase impulsive behavior (reflected by
premature responses) (Paine and Olmstead 2004) and stereotyped behavior (reflected by
persistent head entries) (Fibiger et al. 1973). No such synergistic effects were seen with JDTic
and salvA. The unique pattern of behavior caused by the interaction of JDTic and ketamine
again highlights the fact that the behavioral outcomes under study in the 5CSRTT can vary
independently.
The ability of JDTic to block at least some effects of ketamine was unexpected, and raised the
possibility that ketamine has actions at KORs. High-throughput in vitro screening at the NIMH-
PDSP indicates that ketamine binds to human KORs, albeit much less potently than salvA.
The salvA data confirm previous reports indicating that this substance is highly selective for
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KORs (Roth et al. 2002; Chavkin et al. 2004). We report here that salvA has no affinity for
σ-opioid and NMDA receptors; additionally, pilot data indicate that it has no affinity for rat
DA D2 receptors or the long form of human D2 receptors (B. L. Roth, unpublished
observations). Functional assays conducted in parallel indicate that ketamine is a full agonist
at KORs, as efficacious as salvA, and that these effects are completely blocked at a
concentration of JDTic that also blocks the agonist effects of salvA. The reasons for the smaller
difference in potency between salvA and ketamine in vivo are unknown, but may be due to
uncharacterized differences in bioavailability and metabolism.
Sub-threshold doses of salvA and ketamine that did not have detectable effects in the standard
version of the 5CSRTT also did not degrade performance in versions of the task that were made
more difficult by shortening the duration of the light stimulus (short DS) or lengthening the
wait between light stimuli (long ITI). For these tests, we administered 1.0 mg/kg salvA because
there was a clear distinction between doses with and without effects on the 5CSRTT, whereas
we administered 5.0 mg/kg ketamine because there was a detectable (though non-significant)
trend for the drug to increase latencies at 10 mg/kg. There was a small but statistically
significant effect of 5.0 mg/kg ketamine on latency to collect the reward that is counterintuitive:
the drug shortened latencies, reflecting an improvement in performance. One potential
explanation for this effect is that ketamine might have motor-activating effects at this dose that
are not apparent at higher doses. Indeed, higher doses of ketamine (~80 mg/kg) are often used
together with xylazine to produce anesthesia in rats (Todtenkopf et al. 2004; Davis 2008). Each
of the modified versions seemed more difficult than the standard versions, considering the
differences in baseline performance metrics. For example, in the standard version of the
5CSRTT used in Experiments 1, 3, and 4, baseline correct responding was ~75–80%, whereas
it ranged from ~60 to 70% in the short DS and long ITI versions. The fact that this increase in
task difficulty did not cause behavioral effects to emerge at sub-threshold doses of salvA or
ketamine suggests that certain levels of receptor occupancy are required in order to produce
the drug effects seen in the standard version of the 5CSRTT.
The similarities between salvA and ketamine in the 5CSRTT are somewhat surprising when
considering some of the other behavioral effects of these drugs in laboratory animals. SalvA
and other KOR agonists produce acute depressive-like effects, including increased immobility
behavior in the forced swim test, reduced sensitivity to rewarding brain stimulation, and
reduced sensitivity to the rewarding effects of drugs of abuse and sexual behavior (Leyton and
Stewart 1992; Mague et al. 2003; Todtenkopf et al. 2004; Carlezon et al. 2006, Shippenberg
et al. 1996; Tomasiewicz et al. 2008). In the case of salvA, doses of the drug that cause these
effects on motivation and cognition also reduce extracellular concentrations of DA in the NAc
(Carlezon et al. 2006), an effect often associated with aversion and dysphoria (Carlezon and
Thomas 2009). In contrast, ketamine produces acute antidepressant-like effects (Maeng et al.
2007), stimulation of locomotor activity (Hetzler and Wautlet 1985), and increased sensitivity
to rewarding brain stimulation (Herberg and Rose 1989) over a range of doses comparable to
those used in the present study. It also increases DA efflux in the NAc (Hancock and Stamford
1999), an effect often associated with reward and pleasure (Wise 2008). There is evidence in
rats that ketamine and other non-competitive NMDA receptor antagonists (e.g., MK-801,
phencyclidine) substitute for the KOR agonist U50,488 in drug discrimination tests (Mori et
al. 2006), suggesting similar discriminative stimulus properties in this species. It is conceivable
that the drug discrimination test and the 5CSRTT are both most sensitive to the dissociative
effects of these drugs in rats. Our data suggest that overlap in the behavioral effects of salvA
and ketamine is explained, at least in part, by common actions at KOR receptors.
Ketamine produces rapid and long-lasting antidepressant effects in humans (Zarate et al.
2006). The relationship between the antidepressant effects and the dissociative effects of
ketamine (Lahti et al. 2001) is currently unclear. KOR agonists produce acute depressive effects
Nemeth et al. Page 9













(dysphoria, anxiety) in addition to dissociative effects in humans (Pfeiffer et al. 1986;
Wadenberg 2003; González et al. 2006). However, emerging evidence from studies in
laboratory animals suggests that prior exposure to KOR agonists can produce long-term effects
that are opposite to the acute effects (McLaughlin et al. 2006; Potter et al. 2009), perhaps due
to induction of persistent alterations in KOR-linked signaling pathways (see Knoll and
Carlezon 2010). Such effects may help to explain anecdotal reports of antidepressant effects
in humans (Hanes 2001). Regardless, additional studies of salvA and ketamine on complex
behavior may provide deeper insight into the biological basis of mood states and disorders
characterized by abnormalities of attention, perception, and cognition.
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Effects of salvA on performance in the 5CSRTT. Rats (N=10) were given IP injections of the
drug 10 min before testing. **P<0.01 compared to vehicle (75% DMSO), Fisher’s protected
t tests
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Effects of ketamine on performance in the 5CSRTT. Rats (N=9) were given IP injections of
the drug 10 min before testing. *P<0.05, **P<0.01, tP<0.10 compared to vehicle (0.9% saline),
Fisher’s protected t tests
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Effects of pre-feeding on performance in the 5CSRTT. Rats (N=19) were given their daily
ration of food (~17 g) 30 min before testing. *P<0.05, **P<0.01 compared to baseline (average
of the previous 3-day performance), Fisher’s protected t tests
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Effects of JDTic pre-treatment on the ability of salvA to affect performance in the 5CSRTT
(N=8). **P<0.01 compared to baseline (average of the previous 3-day performance), Fisher’s
protected t tests
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Effects of JDTic pre-treatment on the ability of ketamine to affect performance in the 5CSRTT
(N=8). **P<0.01 compared to baseline (average of the previous 3-day performance), Fisher’s
protected t tests
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Synergistic effects of JDTic and ketamine in the 5CSRTT (N=8). *P<0.05 compared to baseline
(average of the previous 3-day performance), Fisher’s protected t tests
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Functional assay demonstrating that both salvA and ketamine have full agonist effects at KORs,
as reflected by regulation of [35S] GTPγS binding to membranes of CHO-hKOR cells. The
KOR agonist effects of both drugs were completely blocked by JDTic (10 nM)
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Table 3
Affinities (Ki) and potencies (EC50) of salvA and ketamine
Human KOR, [3H] bremazocine Rat σ, [3H] pentazocine Rat NMDA, [3H] MK-801
Ki, nM EC50, nMa Ki, nM Ki, nM
SalvA 0.44 1.5 -b -b
Ketamine 25,000 29,000 5.2 890
a
aEC50 values in activating the hKOR to enhance [35 S] GTPγS binding. Ketamine and salvA produced similar maximal response.
b
SalvA (10 µM) displaced <50% [3 H] radioligand binding (Roth et al. 2002).
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